Connect Biopharma to Present at the Leerink Partners Global Healthcare Conference
Connect Biopharma (Nasdaq: CNTB) management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on March 10, 2026 at 8:00 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Connect Biopharma (Nasdaq: CNTB) management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on March 10, 2026 at 8:00 a.m. ET.
A live webcast will be available via the company investor website and an archived replay will remain accessible for approximately 90 days.
Details
News Market Reaction – CNTB
On Mar 3, the day this news came out, CNTB closed 0.80% below the previous close.
Data tracked by StockTitan Argus for the Mar 3 session.
Key Figures
- Conference date
- March 10, 2026
- Leerink Partners Global Healthcare Conference presentation
- Presentation time
- 8:00 a.m. ET
- Scheduled fireside chat start time
- Replay availability
- approximately 90 days
- Archived webcast available after conference
Historical Context
-
Oppenheimer healthcare conference fireside chat announcement with webcast details.
-
New mechanism-of-action data for rademikibart and 2026 clinical priorities.
-
Evercore Healthcare Conference fireside chat with webcast and 90-day replay.
-
Q3 2025 results, Seabreeze STAT progress, China NDA status, and cash runway.
-
ERS 2025 Phase 2b asthma data with FEV1 gains and fewer exacerbations.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Tuesday, March 10, 2026 at 8:00 a.m. ET.
The live webcast of the presentation may be accessed via the Investors section of the Connect website at investors.connectbiopharma.com. An archived replay of the event will be available on the website for approximately 90 days following the conference.
About Connect Biopharma
Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the Company is advancing rademikibart, a next-generation, potentially best-in-class antibody designed to target IL-4Rα. The Company is currently conducting global clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD, areas with significant unmet need. Connect has granted an exclusive license to Simcere Pharmaceutical Co., Ltd., for rademikibart in Greater China. Under the exclusive license and collaboration agreement, Connect is eligible to receive remaining milestone payments up to an aggregate amount of approximately
For more information visit www.connectbiopharma.com.
Investor Relations Contact:
Alex Lobo
Precision AQ
Alex.lobo@precisionaq.com
(212) 698-8802
Media Contact:
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310 or (646) 942-5604
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.